CIDP treatment focuses on reducing and slowing the immune processes damaging your peripheral nervous system. It includes corticosteroids, intravenous immunoglobulin, and plasma exchange ...

Immunovant anticipates initiating clinical trials evaluating IMVT-1402 in a total of ten indications by March 31, 2026. Neurology Program: ...

Reports Q3 revenue $9.02M, consensus $4.75M. “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in ...

Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, has announced a collaboration with ...

Stephanie Lee Griffin; Chief Operating Officer; Roivant Sciences Ltd. Matt Gline; Chief Executive Officer, Director; Roivant Sciences Ltd. Dave Risinger; Analyst; Le ...

H.C. Wainwright reaffirmed their Buy rating on Immunovant (NASDAQ:IMVT) shares with a price target of $51.00, aligning with the broader Wall Street sentiment. According to InvestingPro data, analyst ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

THE family of a "beloved father and husband" who took his own life after Covid-19 vaccine complications are fighting for justice.

It said: Our Buy thesis is driven by (1) Double digit IG growth (GSe: +12.6% FY23-FY28E CAGR) underpinned by low penetration (including CIDP ... that sleep disorder treatment company ResMed ...

But doctors are rushed in appointments, and having to make a diagnosis and come up with a treatment plan already takes up more time than is allotted for most appointments. And with a disease like CIDP ...

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a look at where Ascendis Pharma A/S (NASDAQ:ASND) stands against other high ...

Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.